12.01.23
Dr. Jens Schulte will leave the Board of Management of SCHOTT AG at the end of the 2024 fiscal year at his request to pursue new professional challenges. Schulte has decided to take on the role of CFO at thyssenkrupp AG in the future.
“On behalf of the Supervisory Board, I would like to thank Mr. Schulte very much for his work,” said Michael Bolle, chairman of the Supervisory Board of SCHOTT AG. “As CFO, he has made a significant contribution to the company and accompanied the successful IPO of SCHOTT Pharma. We respect Mr. Schulte’s decision and wish him much success in his personal and professional future.”
“After more than eight years, I have decided to leave SCHOTT and would like to thank the entire Board of Management team and my colleagues for their support. We have achieved a lot together during this time, which we can be very proud of,” said Dr. Schulte.
“On behalf of the Supervisory Board, I would like to thank Mr. Schulte very much for his work,” said Michael Bolle, chairman of the Supervisory Board of SCHOTT AG. “As CFO, he has made a significant contribution to the company and accompanied the successful IPO of SCHOTT Pharma. We respect Mr. Schulte’s decision and wish him much success in his personal and professional future.”
“After more than eight years, I have decided to leave SCHOTT and would like to thank the entire Board of Management team and my colleagues for their support. We have achieved a lot together during this time, which we can be very proud of,” said Dr. Schulte.